Acella Pharmaceuticals, LLC has submitted an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) for a topical corticosteroids lotion.
Mark Pugh, CEO of Acella Pharmaceuticals, commented, “Our R&D team has done a tremendous job in effectively managing our development projects, resulting in an extensive product pipeline. This filing represents Acella’s sixth ANDA filed with the FDA. We expect to file additional ANDAs this year to bring our total to 11 ANDA submissions by the end of 2012.”
“We look forward to working with the FDA to get this product approved, on the market, and to our customers,” stated Allen Fields, vice president, Head of Research and Development, Acella Pharmaceutical. “We continue to meet the objectives of our development strategy by finding the right products to assist patients with managing their health care costs.”
Acella develops, markets, sells and distributes a broad portfolio of non-branded pharmaceutical and other products in the areas of dermatology, women’s health, paediatrics and other applications.